Migraine – AbbVie Aurora D7060C00003
Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.
The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.
Inclusion Criteria:
- 18 to 70 years of age
- Weight ≥ 40 kg and BMI ≥ 18.0 kg/m2.
- History of migraine headaches with or without aura, with migraine onset at ≤ 50 years of age and for at least 12 months prior to screening.
- At least 12 MHDs over the last 3 months prior to screening.
- Participants must be able to distinguish migraine headaches from tension-type headaches.
- Female participants who are not pregnant and do not plan to become pregnant during the study, are not lactating, or are of nonchildbearing potential.
- FOCBP who are sexually active with a non-sterilised male partner must use adequate contraception consisting of two highly effective methods of contraception throughout the study. FOCBP must agree to comply with protocol specified guidance for safe administration of MEDI0618.
- Other criteria may apply
Complete the form and our team will reach out soon to help determine your eligibility.
